Blue Jet Healthcare Q4 FY26: Contrast Media Strength Offsets Pharma Timing Dip

Blue Jet Healthcare ended Q4 FY26 with a clear message on mix and execution. Quarterly revenue from operations came in at Rs. 2,347 mn, with EBITDA of Rs. 713 mn and PAT of Rs. 643 mn. Margins stayed healthy even as the year-on-year base looked demanding. EBITDA margin stood at 30 percent and PAT margin at 27 percent. The company attributed the quarter’s sequential lift to higher sales of advanced contrast media intermediates, a category where it has long customer relationships and growing wallet share.

The year-on-year comparison was weaker. Q4 FY26 revenue fell 31 percent versus Q4 FY25, while EBITDA dropped 49 percent and PAT declined 42 percent. Management linked the decline to negligible sales of one molecule in the pharma intermediates vertical, along with timing-related order phasing in select accounts and customer-side inventory normalization. The company said it continues to have strong visibility on underlying demand and expects normalization to show up in the coming quarters.

What stands out is the gap between quarter-on-quarter improvement and year-on-year weakness. Q4 FY26 improved sharply versus Q3 FY26. Revenue rose 22 percent sequentially, EBITDA grew 52 percent, and PAT rose 60 percent. Gross margin expanded to 56 percent from 52 percent in Q3, helped by favourable product mix and higher contrast media intermediates sales. The company also pointed to lower employee costs and operating leverage as factors supporting margin recovery.

Q4 and FY26 performance: A mix story more than a demand story

In Q4 FY26, Blue Jet’s profitability was shaped by two forces moving in opposite directions. Contrast media intermediates expanded strongly, while pharma intermediates and API revenue nearly disappeared for the quarter. Segment numbers show the split clearly. Contrast media intermediates revenue rose to Rs. 1,928 mn in Q4 FY26 from Rs. 1,011 mn in Q4 FY25. High-intensity sweeteners also grew from Rs. 297 mn to Rs. 368 mn. But pharma intermediates and API dropped to Rs. 24 mn from Rs. 1,959 mn a year earlier. That shift explains why overall revenue declined year-on-year even as gross margin stayed stable.

Full-year FY26 results were more balanced, but still reflected the same theme. FY26 revenue from operations was Rs. 9,473 mn versus Rs. 10,300 mn in FY25, a decline of 8 percent. EBITDA declined to Rs. 2,941 mn from Rs. 3,777 mn, and PAT eased to Rs. 2,478 mn from Rs. 3,052 mn. EBITDA margin moved down to 31 percent from 37 percent, largely due to higher operating costs alongside lower volumes in the pharma intermediates and API segment. Gross margin remained broadly stable at 54 percent versus 55 percent in FY25.

Another important line item in FY26 was other income, which rose to about Rs. 687 mn from about Rs. 463 mn. The company attributed this increase mainly to foreign exchange gains. It helped cushion the impact of lower operating profit versus the prior year.

Segment lens: Contrast media resilience, sweeteners steady, pharma uneven

Blue Jet’s three operating categories behaved very differently in FY26. Contrast media intermediates became the anchor. For FY26, contrast media intermediates revenue rose to Rs. 4,951 mn from Rs. 4,039 mn in FY25. In the company’s own revenue mix summary, this segment contributed 52.50 percent of FY26 revenue. The contrast media market is described as highly concentrated, with the top four players accounting for around 75 percent of global market share, and Blue Jet highlights relationships of 4 to 27 years with three of the largest manufacturers.

The company’s positioning rests on high entry barriers. It stresses strict impurity standards, long-term supply contracts, and customer validation. It also states that around 70 percent of total sales are backed by contracted volumes. The strategic direction within contrast media is consistent: forward integration into more advanced intermediates. Blue Jet started with a key starting intermediate in 2000 and had 19 commercialized products in the category as of FY26, aiming to capture higher realization and profitability per unit through deeper wallet share with existing customers.

High-intensity sweeteners were stable. FY26 revenue was Rs. 1,314 mn versus Rs. 1,335 mn in FY25. The segment contributed 13.90 percent of FY26 revenue and serves more than 300 customers globally. The business is built around saccharin and its salts, and Blue Jet highlights consistency in taste and impurity profile, a semi-automated manufacturing setup, and compliance credentials including receipt of a US-FDA inspection report.

Pharma intermediates and API remained the swing factor. FY26 revenue dropped to Rs. 2,978 mn from Rs. 4,622 mn in FY25, and the Q4 number was particularly low due to the absence of one molecule. Yet the company presented this as a timing and inventory normalization issue rather than a structural loss of demand. In business updates, it stated that de-stocking and inventory normalization by the customer have been completed, and robust revenues are expected backed by orders in the coming quarters.

Execution and capacity: Projects, R and D build-out, and operating leverage

Management’s FY26 narrative was not only about near-term results but also about what is being built for the next cycle. Two project updates matter. The Vizag project has completed its ground-breaking ceremony and project activities have commenced. Separately, the company’s R and D centre in Hyderabad has started civil construction and is expected to be completed on or before September 2026, with hiring of key resources initiated.

This emphasis fits the company’s operating model. Blue Jet describes itself as a specialty pharmaceutical and healthcare ingredient and intermediate company, with an approach of collaboration, development, and manufacturing aligned to CDMO work. Across categories, it relies on chemistry depth and long customer relationships rather than commodity scale. Its stated R and D framework spans process research, analytical research, and chemistry research. The list of capabilities includes process scale-up and validation, impurity characterization, stability studies, polymorphism and salt screening, cryogenic and high-pressure reactions, and a range of complex transformations such as catalytic hydrogenation, iodination, bromination, chlorination, and diazotization.

Even in a year when EBITDA margin fell, Q4 showed the operating model can still generate leverage when volumes and mix cooperate. Gross margin expanded quarter-on-quarter to 56 percent, and EBITDA margin improved to 30 percent. The company said lower employee cost and the benefit of higher sales volume and operating leverage supported this improvement.

The balance sheet also shows liquidity and an investment posture. As of March 31, 2026, cash and cash equivalents plus treasury investments were Rs. 3,619 mn. Total assets increased to Rs. 16,412 mn, with total equity at Rs. 13,599 mn. The company reported no borrowings as of FY26, a notable difference from earlier years.

Sustainability initiatives were also highlighted, mainly in the context of energy efficiency and resource management. The company invested in windmills with installed capacity of 3.3 MW, created carbon sinks through tree plantations, and operates effluent treatment plants with modern standards. It also noted a focus on minimizing solvents and using recycled solvents and water.

What to watch: Normalization in pharma and the next leg in contrast media

Blue Jet’s Q4 and FY26 results can be read as a transition year where segment mix did most of the talking. Contrast media intermediates performed as the stabilizer and growth engine, supported by customer stickiness, long contracts, and forward integration into advanced intermediates. High-intensity sweeteners remained steady, adding a broad customer base and stable cash flows.

The open question remains pharma intermediates and API. In FY26 the segment declined sharply, and Q4 showed how quickly revenue can compress when one molecule does not ship. The company’s own explanation is important: order phasing and customer inventory normalization. Management also stated that normalization is completed and orders are in hand for coming quarters. If that plays out, the FY26 margin decline could prove cyclical rather than structural.

For investors, the quarter’s theme is mix-driven recovery with continued investment in capabilities. Q4 showed sharper sequential profitability as contrast media volumes improved, while FY26 reflected the cost of lower pharma volumes. With the Vizag project underway and the Hyderabad R and D centre targeted for completion by September 2026, the company is signalling continued focus on chemistry depth and capacity to support customer programs. The next few quarters should clarify whether pharma intermediates revert to expected levels and whether contrast media forward integration continues to lift wallet share and margins.